In a move set to redefine the landscape of cardiovascular intervention, Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) have announced a monumental agreement. Under this definitive agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for an impressive $335.00 per share in cash, totaling approximately $13.1 billion, including cash acquired. The decision, unanimously approved by both companies’ boards of directors, marks a significant milestone in the realm of medical technology.
Pioneering Innovation in Cardiovascular Intervention
The acquisition of Shockwave by Johnson & Johnson heralds a new era in cardiovascular intervention. With cardiovascular intervention ranking among the fastest-growing global medtech markets, this strategic move positions Johnson & Johnson MedTech at the forefront of innovation and growth. The addition of Shockwave to its portfolio propels Johnson & Johnson into two of the most dynamic and innovation-driven segments of cardiovascular intervention: coronary artery disease (CAD) and peripheral artery disease (PAD). This acquisition seamlessly aligns with Johnson & Johnson’s ongoing commitment to addressing unmet patient needs and driving medical advancements.
Empowering Patients with Revolutionary Technology
Shockwave Medical is currently the only competitor within the IVL market and gained a position in the peripheral vascular device market. It distributes its Peripheral Lithoplasty® Balloon Dilation Catheter for use with the Peripheral Lithoplasty® System. The company first obtained FDA approval for peripheral use in September 2016. Since then, the company has launched a number of other trials, including the DISRUPT II and III, further testing IVL use in the fem-pop artery, and the DISRUPT BTK and BTK II trial, obtaining clinical evidence for IVL use BTK. Shockwave’s Lithoplasty® balloon was also approved for coronary use in September 2019.
Expanding Horizons: The Next Frontier in Patient Care
In addition to its groundbreaking IVL technology, Shockwave’s recent acquisition of Neovasc Inc. further solidifies its commitment to innovation and patient-centric care. Neovasc Inc. brings to the table the Reducer System, a revolutionary product designed to provide symptom relief for refractory angina patients. With a growing commercial presence and ongoing clinical studies, the Reducer System complements Shockwave’s existing portfolio, promising enhanced outcomes for patients worldwide.
A Vision for the Future: Redefining Healthcare Together
This landmark acquisition underscores Johnson & Johnson’s unwavering dedication to advancing healthcare and improving patient outcomes. By combining Shockwave’s innovative technologies with Johnson & Johnson’s global reach and resources, the stage is set for transformative advancements in cardiovascular care. Together, these industry leaders are poised to shape the future of healthcare, setting new standards of excellence and innovation along the way.
To learn more about the global peripheral vascular market, our 2024 report was just updated and published. It contains insights into the most significant M&A activity along with insights into ASPs, market size projections, market drivers, market limiters, and complete portfolios into all of the major market players. Click the button below to receive a complimentary executive summary of the report.
